Ensign Peak Advisors
BBOT

Ensign Peak Advisors’s BridgeBio Oncology BBOT Stock Holding History

Ensign Peak Advisors’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.08M Sell
273,530
-47,344
-15% -$395K ﹤0.01% 731
2026
Q1 		$2.87M Buy
+320,874
New +$3.45M 0.01% 642

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ensign Peak Advisors's BBOT Position: Q2 2026 in Review

Ensign Peak Advisors reduced its BridgeBio Oncology (BBOT) stake by 15% in Q2 2026, selling an estimated $395K and leaving 273,530 shares worth $2.08M. The position accounts for ﹤0.01% of the portfolio, ranked #731.

Ensign Peak Advisors first reported a position in BBOT in Q1 2026 and has held it in 2 quarters since. The position peaked at $2.87M in Q1 2026. 66 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Ensign Peak Advisors held 273,530 shares of BridgeBio Oncology worth $2.08M as of Q2 2026.
  • Ensign Peak Advisors sold 47,344 BridgeBio Oncology shares in Q2 2026, an estimated $395K.
  • BridgeBio Oncology made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #731 holding.
  • Ensign Peak Advisors first reported a position in BridgeBio Oncology in Q1 2026 and has held it in 2 quarters since.
  • Ensign Peak Advisors's BridgeBio Oncology position peaked at $2.87M in Q1 2026.
  • 66 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.